Odimont-LC Kid Tablet is a combination medication containing Levocetirizine 2.5 mg and Montelukast 5 mg, formulated specifically for pediatric use in the management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor CysLT1, reducing airway inflammation and bronchoconstriction commonly observed in asthma and allergic rhinitis. The synergistic effect of these two agents provides comprehensive relief from allergic manifestations by targeting both histaminergic and leukotriene-mediated pathways. Odimont-LC Kid Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis and for the prophylaxis and chronic treatment of asthma in children. It is generally well tolerated, with a favorable safety profile when administered at recommended dosages. Common adverse effects may include headache, fatigue, and gastrointestinal disturbances, though these are typically mild and transient. Use of Odimont-LC Kid Tablet should be guided by a healthcare professional, with consideration of the child’s medical history and concomitant medications to ensure optimal therapeutic outcomes.